Sotsiaalministeerium
Meie: 15.04.2020
nr 7-5.13/20-00847-2
Ettepaneku edastamine
Edastan peaministrile Eurofins Estonia analüüse teostavalt laboratooriumilt saabunud
ettepaneku.
Lugupidamisega
(allkirjastatud digitaalselt)
Heili Tõnisson
Valitsuse nõunik
Teadmiseks:
Rahandusministeerium
Stenbocki maja / Rahukohtu 3 / 15161 Tallinn / Estonia / registrikood 700004809
+372 693 5555 /
[email protected] / www.riigikantselei.ee
Eurofins Technologies launches multiple new products for the serologic
detection of antibodies in patients who have been exposed to COVID-19.
Viracor Eurofins received FDA EUA for its RT-PCR SARS-CoV-2 Virus LDT.
Eurofins Genomics expands capacity for probes and primers production for
RT-PCR SARS-CoV-2 test kits
09 April 2020
Eurofins Technologies, a fast growing provider of diagnostic technologies in the field of immunoassays
and molecular detection methods, announces the launch of a range of testing kits for serology-based
antibody detection by ELISA of patients who have been exposed to COVID-19. The development of the
assays has been spearheaded by affiliate companies Gold Standard Diagnostics Inc., Virotech
Diagnostics GmbH, NovaTec Immundiagnostica GmbH and Ingenasa (Inmunologia Y Genetica
Aplicada SA). Those specialized diagnostic technologies companies are well-established providers of
testing solutions with a strong focus on scientific excellence in infectious diseases testing and
immunology. The first ELISA assays are expected to receive CE-IVD mark by 16 April 2020 and will
also be submitted to the U.S. Food and Drug Administration (FDA) for Emergency Use Authorisation
(EUA).
Viracor Eurofins received FDA EUA for its RT-PCR Laboratory-Developed Test (LDT) for SARS-CoV-2
on 06 April 2020. More information can be found on https://www.viracor-eurofins.com/about-
us/newsroom/news-items/viracor-eurofins-receives-emergency-use-authorization-eua-from-the-us-food-
and-drug-administration-fda-for-its-sars-cov-2-rt-pcr-laboratory-developed-test-ldt/.
Due to the increasing global demand and worsening supply chain issues, Eurofins Genomics’ six
oligonucleotides production sites in the U.S., Europe, India and Japan are increasing their capacity to
produce probes, primers and positive controls, which are key components for RT-PCR testing of SARS-
CoV-2.
Multiple solutions to support health authorities in their fight against COVID-19
A comprehensive product portfolio is essential to support the tremendous efforts of health authorities
working on SARS-CoV-2 detection and COVID-19 control all over the world. Over the last six weeks, in
close collaboration with leading research hospitals and many of Eurofins human clinical testing
laboratories around the world, Eurofins Technologies teams have worked diligently to develop a broad
range of testing methods to support healthcare providers around the world.
According to experts, there is a large range of applications for serologic testing. Serology can be used
to complement the PCR swab testing that detects the virus to help diagnose acute infections status and
its evolution. It can help estimate the timing of infection. As knowledge develops about the immunity to
potential reinfection of patients having previously contracted COVID-19 and recovered, antibodies
testing may provide information about statistically reduced contagion risks of and from these persons. It
Eurofins Scientific 1/3 April 2020
could help identify donors of plasma from recovered patients that can be transfused into COVID-19
patients as a potential treatment. Long-term, serologic tools can contribute to discriminating between
vaccine-induced antibodies and natural infection. As the pandemic unfolds, serosurveys can enable
tracking closely what percentage of the population has become infected in each city or region.
Serosurveys may also help efforts to develop vaccines and therapies.
The following products will be released shortly to leading reference centres and hospitals
around the world:
Serology – Antibody tests for IgG, IgM, and IgA with very good specificity and sensitivity will be
released for use on any open ELISA platform.
Lateral Flow – As an additional option with fast turnaround time, an easy-to-use rapid lateral flow
antibodies test is under final development and validation.
Automation – Gold Standard Diagnostics offers a suite of instruments for the seamless automation of
ELISA assay testing in any laboratory.
Molecular Diagnostics – A range of RT-PCR tests for the qualitative detection of SARS-CoV-2 have
been developed by Eurofins laboratories around the world. These tests are designed to meet the
region-specific requirements for COVID-19 targets. Viracor Eurofins received FDA Emergency Use
Authorization (EUA) for its SARS-CoV-2 Laboratory Developed Test (LDT) on 06 April 2020. Other
Eurofins laboratories around the world have developed alternative RT-PCR options to meet local
regulatory obligations and mitigate reagent supply chain issues so Eurofins can continue to significantly
increase the testing capacity it offers to health authorities fighting the disease.
Probes and Primers for RT-PCR - Eurofins Genomics is also supplying primers and probes to a large
number of laboratories and clinical diagnostic developers around the world to form an essential part of
their RT-PCR testing solutions. Eurofins Genomics’ six Oligonucleotides production sites around the
world are increasing capacity significantly to meet the growing demand and help clinical diagnostic
manufacturers and laboratories mitigate supply chain issues.
For more information, please visit www.eurofins.com or contact:
Investor Relations
Eurofins Scientific
Phone: +32 2 766 1620
E-mail:
[email protected]
Notes for the editor:
About Eurofins Technologies – a fast growing provider of diagnostic technologies in the field of immunoassays
and molecular detection methods
Building on the experience and scientific excellence of the Eurofins Group, Eurofins Technologies is a fast growing global
provider of diagnostic technologies and industry-leading ELISA-based instruments in the field of bioanalytical testing for the
food, feed, environmental, animal health, and clinical diagnostics industries.
Its R&D teams located at various sites around the world share their expertise in developing a wide range of innovative
methods and applications with a focus on immunoassays and molecular testing. For further information, please visit the
Eurofins Technologies website.
About Eurofins Genomics – a global leader in DNA sequencing services, next generation sequencing services,
genotyping services, DNA synthesis products and bioinformatics services
Eurofins Scientific 2/3 April 2020
Eurofins Genomics, a member of the Eurofins Group with facilities in Europe, the United States and Asia, is an
internationally leading provider of DNA sequencing services, next generation sequencing services, genotyping services,
DNA synthesis products and bioinformatics services for pharma, diagnostics, food, agriculture, biotechnological and
research markets. The company's strength is its extensive customer base and high quality services in industrial scale for the
life science industries and academic research institutions around the world. For further information, please visit the Eurofins
Genomics website.
About Eurofins – a global leader in bio-analysis
Eurofins Scientific, through its subsidiaries (hereinafter “Eurofins” or “the Group”), believes it is a global leader in food,
environmental, pharmaceutical and cosmetics products testing and in agroscience CRO services. It is also one of the global
independent market leaders in certain testing and laboratory services for genomics, discovery pharmacology, forensics,
CDMO, advanced material sciences and in the support of clinical studies. In addition, Eurofins is one of the leading global
emerging players in esoteric clinical diagnostic testing. With over 47,000 staff across a network of more than 900
independent companies in over 50 countries generally specialised by end client markets and operating more than 800
laboratories, Eurofins offers a portfolio of over 200,000 analytical methods to evaluate the safety, identity, composition,
authenticity, origin, traceability and purity of biological substances and products, as well as providing innovative clinical
diagnostic testing services. The Group’s objective is to provide customers with high-quality and innovative services, accurate
results on time and, when requested, expert advice by its highly-qualified staff.
Eurofins is committed to pursuing its dynamic growth strategy by expanding both its technology portfolio and its geographic
reach. Through R&D and acquisitions, the Group draws on the latest developments in the field of biotechnology and
analytical chemistry to offer its clients unique analytical solutions and a very large range of testing methods.
As one of the most innovative and quality-oriented international companies in its industry, Eurofins is ideally positioned to
support its clients’ increasingly stringent quality and safety standards and the increasing demands of regulatory authorities
and healthcare practitioners around the world.
Shares in Eurofins Scientific are listed on the Euronext Paris Stock Exchange (ISIN FR0000038259, Reuters EUFI.PA,
Bloomberg ERF FP).
Until it has been lawfully made public widely by Eurofins through approved distribution channels, this document contains
inside information for the purpose of Regulation (EU) 596/2014 of the European Parliament and of the Council of 16 April
2014 on market abuse, as amended.
Important disclaimer:
This press release contains forward-looking statements and estimates that involve risks and uncertainties. The forward-
looking statements and estimates contained herein represent the judgment of Eurofins Scientific’s management as of the
date of this release. These forward-looking statements are not guarantees for future performance, and the forward-looking
events discussed in this release may not occur. Eurofins Scientific disclaims any intent or obligation to update any of these
forward-looking statements and estimates. All statements and estimates are made based on the information available to the
Company’s management as of the date of publication, but no guarantees can be made as to their completeness or validity.
Eurofins Scientific 3/3 April 2020
Eurofins Scientific Offers a full range of Testing services
for Personal Protective Equipment (PPEs) and Medical Devices used in the
fight against the COVID pandemic
06 April 2020
Eurofins, a global leader in testing and laboratory services, announces that its laboratories across the
U.S.A., Europe and Asia are now providing a global service offer for testing, inspection and regulatory
services focused on medical face masks, gloves and gowns, respiratory protective devices and
equipment, its materials and components, as well as disinfectants and hand sanitizers, to serve the
increasing demand caused by the severe coronavirus pandemic.
With a service offering that covers a scope spanning from product concept and risk assessment,
Notified Body services, through chemical, biological, physical, mechanical or electrical testing, efficacy
and performance evaluations and all the way down to product certification and quality controls, Eurofins
strives to be the one-stop solution provider for its clients supplying PPEs and Medical Devices to the
healthcare sector worldwide.
More information on this global service offer is available on https://www.eurofins.com/COVID-19-
Global-Services
For more information, please visit www.eurofins.com or contact:
Investor Relations
Eurofins Scientific
Phone: +32 2 766 1620
E-mail:
[email protected]
Notes for the editor:
About Eurofins – a global leader in bio-analysis
Eurofins Scientific, through its subsidiaries (hereinafter “Eurofins” or “the Group”), believes it is a global leader in food,
environmental, pharmaceutical and cosmetics products testing and in agroscience CRO services. It is also one of the global
independent market leaders in certain testing and laboratory services for genomics, discovery pharmacology, forensics,
CDMO, advanced material sciences and in the support of clinical studies. In addition, Eurofins is one of the leading global
emerging players in esoteric clinical diagnostic testing. With over 47,000 staff across a network of more than 900
independent companies in over 50 countries generally specialised by end client markets and operating more than 800
laboratories, Eurofins offers a portfolio of over 200,000 analytical methods to evaluate the safety, identity, composition,
authenticity, origin, traceability and purity of biological substances and products, as well as providing innovative clinical
diagnostic testing services. The Group’s objective is to provide customers with high-quality and innovative services, accurate
results on time and, when requested, expert advice by its highly-qualified staff.
Eurofins is committed to pursuing its dynamic growth strategy by expanding both its technology portfolio and its geographic
reach. Through R&D and acquisitions, the Group draws on the latest developments in the field of biotechnology and
analytical chemistry to offer its clients unique analytical solutions and a very large range of testing methods.
Eurofins Scientific 1/2 April 2020
As one of the most innovative and quality-oriented international companies in its industry, Eurofins is ideally positioned to
support its clients’ increasingly stringent quality and safety standards and the increasing demands of regulatory authorities
and healthcare practitioners around the world.
Shares in Eurofins Scientific are listed on the Euronext Paris Stock Exchange (ISIN FR0000038259, Reuters EUFI.PA,
Bloomberg ERF FP).
Until it has been lawfully made public widely by Eurofins through approved distribution channels, this document contains
inside information for the purpose of Regulation (EU) 596/2014 of the European Parliament and of the Council of 16 April
2014 on market abuse, as amended.
Important disclaimer:
This press release contains forward-looking statements and estimates that involve risks and uncertainties. The forward-
looking statements and estimates contained herein represent the judgment of Eurofins Scientific’s management as of the
date of this release. These forward-looking statements are not guarantees for future performance, and the forward-looking
events discussed in this release may not occur. Eurofins Scientific disclaims any intent or obligation to update any of these
forward-looking statements and estimates. All statements and estimates are made based on the information available to the
Company’s management as of the date of publication, but no guarantees can be made as to their completeness or validity.
Eurofins Scientific 2/2 April 2020
Eurofins Scientific Supports Healthcare Authorities in Europe, the U.S.A. and
Brazil in their Fight against the COVID-19 Pandemic with Additional Testing
Options and Fast Growing Capacity
19 March 2020
Eurofins, a global leader in testing and laboratory services, announces that, in addition to the U.S.A.
and Germany, as previously communicated, it is now offering testing for detection of SARS-CoV-2 in
France, Spain and Brazil with the Netherlands expected to start processing samples shortly. Global
capacity created is currently around 10,000 tests per day split about equally between Europe and
America. Following requests from government health authorities, Eurofins teams are working round the
clock to increase capacity. It is now expected to increase to well over 15,000 tests per day by Monday
23 March 2020 and significantly more by 01 April 2020 as new sites and testing methods are added. In
each geography, Eurofins laboratories are working closely with public health authorities and following
their priorities to support hospitals and medical professionals fighting this unseen health crisis.
This week, five laboratories started testing for SARS-CoV-2 in France. In particular, Eurofins Biomnis’
laboratories started testing for SARS-CoV-2 using a test they developed and successfully validated and
after receiving approval from the government health authorities. As part of this effort to support
Healthcare authorities, Eurofins Biomnis is enabling French hospitals to free up capacity to perform
SARS-CoV-2 tests on site at short turnaround times by also offering outsourcing for other infectious
diseases testing. In Spain, Eurofins Megalab Madrid also started testing for COVID-19 this week. On 11
March 2020, Eurofins Brazil started offering COVID-19 tests through its Clinical Laboratory Centro de
Genomas.
In the U.S.A., where Eurofins started testing last week, capacity is also ramping up fast to meet growing
demand. Viracor Eurofins, one of the largest and most recognized infectious diseases testing
laboratories in the U.S.A., launched a stand-alone real time reverse transcriptase PCR assay for the
qualitative detection of SARS-CoV-2 in accordance with the FDA Emergency Use Authorization
Guidance on 13 March 2020 (more information available on https://www.viracor-eurofins.com/about-
us/newsroom/news-items/viracor-eurofins-launches-coronavirus-sars-cov-2-rt-pcr-test-with-same-day-
results-12-18-hours/). Earlier this week, Viracor Eurofins also announced a partnership with the
National Kidney Registry (NKR) to deliver testing for Coronavirus SARS-CoV-2 to NKR’s vast network
of Member Centers for critical organ donor testing currently at risk in the U.S.A. (more information
available on https://www.viracor-eurofins.com/about-us/newsroom/news-items/the-national-kidney-
registry-and-viracor-eurofins-announce-coronavirus-covid-19-rapid-turnaround-transplant-testing-for-
donors-and-recipients/). Transplant Genomics has established relationships with Quest and various
other mobile sample collection groups to enable patients to have samples collected remotely for
TruGraf, the only blood test approved by CMS for surveillance to rule out silent rejection in stable
kidney transplant recipients and provide comfort that patients are likely to be immune quiescent.
Eurofins Scientific 1/3 March 2020
Additionally, Transplant Genomics is offering access to SARS-CoV-2 through its sister company Viracor
Eurofins (more information available on http://www.prnewswire.com/news-releases/eurofins-transplant-
genomics-and-viracor-will-partner-to-offer-remote-sample-collection-options-to-support-care-for-kidney-
transplant-recipients-during-covid-19-outbreak-301026371.html?tc=eml_cleartime). Diatherix Eurofins,
a leader in respiratory viral and bacterial testing in the U.S.A., began testing for SARS-CoV-2 that is the
cause of the COVID-19 respiratory infection in accordance with the FDA Emergency Use Authorization
Guidance on 17 March 2020. The COVID-19 Panel is part of its proprietary TEM-PCR respiratory
testing portfolio and offers same day turnaround (10 hours or less after specimen receipt) results. The
COVID-19 Panel includes identification of the SARS-CoV-2 virus along with five bacterial pathogens
which are known to be problematic with upper and lower respiratory tract infections. The additional
testing capabilities of the Diatherix COVID-19 panel results in overall optimal therapy and improved
patient outcomes (more information available on https://www.prnewswire.com/news-releases/diatherix-
eurofins-launches-sars-cov-2-virus-identification-for-the-covid-19-respiratory-infection-301024890.html).
Eurofins U.S. Clinical diagnostic laboratories, including Eurofins VRL, Boston Heart Diagnostics and
EGL Genetics, are working diligently to further expand their testing capacity in the coming weeks for
patients and healthcare professionals. All positive results are being reported pursuant to regulatory
guidelines.
In Germany, Eurofins Medizinisches Labor Gelsenkirchen (Eurofins GeLaMed) started testing for
COVID-19 on 03 March 2020 and while facing fast growing testing volumes, is looking into options to
increase capacity in the near future.
In addition, Eurofins Technologies, a fast growing provider of diagnostic technologies in the field of
immunoassays and molecular detection methods, is finalizing the development and preparing to start
validating new SARS-CoV-2 clinical testing kits and testing kits for detection of SARS-CoV2 in
environmental swabs of surfaces and in food or feed samples.
“As a world leader and innovator in analytical testing, we are pleased to be able to contribute to the
global response to the SARS-CoV-2 crisis by giving healthcare providers around the world options in
evaluating their patients during this terrible outbreak. A growing number of healthcare authorities across
the world are now adopting broader testing regimes to complement social isolation and other measures
and rapidly identify, care for and isolate SARS-CoV-2 positive persons either within front line healthcare
workers or hospitalized patients only or suspected cases and their contacts in the population at large
depending on the country in order to, amongst other objectives, reduce contagion risks. As a Group,
Eurofins is committed to leveraging all of its technical capabilities, including in its genomics and
forensics laboratories, to support current and future SARS-CoV-2 testing needs as defined by
government healthcare authorities and exploring innovative solutions to further increase capacity and
the range of testing options available to support the admirable work of medical teams around the world”,
said Chief Executive Officer Dr. Gilles Martin.
For more information, please visit www.eurofins.com or contact:
Investor Relations
Eurofins Scientific
Phone: +32 2 766 1620
E-mail:
[email protected]
Eurofins Scientific 2/3 March 2020
Notes for the editor:
About Eurofins – a global leader in bio-analysis
Eurofins Scientific, through its subsidiaries (hereinafter “Eurofins” or “the Group”), believes it is a global leader in food,
environmental, pharmaceutical and cosmetics products testing and in agroscience CRO services. It is also one of the global
independent market leaders in certain testing and laboratory services for genomics, discovery pharmacology, forensics,
CDMO, advanced material sciences and in the support of clinical studies. In addition, Eurofins is one of the leading global
emerging players in esoteric clinical diagnostic testing. With over 47,000 staff across a network of more than 900
independent companies in over 50 countries generally specialised by end client markets and operating more than 800
laboratories, Eurofins offers a portfolio of over 200,000 analytical methods to evaluate the safety, identity, composition,
authenticity, origin, traceability and purity of biological substances and products, as well as providing innovative clinical
diagnostic testing services. The Group’s objective is to provide customers with high-quality and innovative services, accurate
results on time and, when requested, expert advice by its highly-qualified staff.
Eurofins is committed to pursuing its dynamic growth strategy by expanding both its technology portfolio and its geographic
reach. Through R&D and acquisitions, the Group draws on the latest developments in the field of biotechnology and
analytical chemistry to offer its clients unique analytical solutions and a very large range of testing methods.
As one of the most innovative and quality-oriented international companies in its industry, Eurofins is ideally positioned to
support its clients’ increasingly stringent quality and safety standards and the increasing demands of regulatory authorities
and healthcare practitioners around the world.
Shares in Eurofins Scientific are listed on the Euronext Paris Stock Exchange (ISIN FR0000038259, Reuters EUFI.PA,
Bloomberg ERF FP).
Until it has been lawfully made public widely by Eurofins through approved distribution channels, this document contains
inside information for the purpose of Regulation (EU) 596/2014 of the European Parliament and of the Council of 16 April
2014 on market abuse, as amended.
Important disclaimer:
This press release contains forward-looking statements and estimates that involve risks and uncertainties. The forward-
looking statements and estimates contained herein represent the judgment of Eurofins Scientific’s management as of the
date of this release. These forward-looking statements are not guarantees for future performance, and the forward-looking
events discussed in this release may not occur. Eurofins Scientific disclaims any intent or obligation to update any of these
forward-looking statements and estimates. All statements and estimates are made based on the information available to the
Company’s management as of the date of publication, but no guarantees can be made as to their completeness or validity.
Eurofins Scientific 3/3 March 2020
Eurofins Technologies launches testing solutions for the detection of SARS-
CoV-2 on environmental surfaces
27 March 2020
Eurofins Technologies, a fast growing provider of diagnostic technologies in the field of immunoassays
and molecular detection methods, has launched GeneScan VIRSeek SARS-CoV-2 RT-PCR, an
integrated solution including RNA extraction and test kits based on real-time RT-PCR (Reverse
transcription polymerase chain reaction) for the detection of SARS-CoV-2 in swabs of environmental
surfaces.
Recently published studies suggest that SARS-CoV-2 may remain viable on different surfaces for up to
72 hours. The comprehensive VIRSeek suite of test kits and workflows provides customers with fast
tests to broadly screen for the presence of SARS-CoV-2, as well as verification of results with an
independent test. This will enable organisations in diverse industries, as well as in healthcare, transport
and many other environments to help test, determine, monitor and eventually strengthen the
effectiveness of sanitation measures put in place, ultimately contributing to increased health and safety
in these respective environments.
“We are pleased to provide companies and health authorities with options to test for the presence of
SARS-CoV-2 in their environments and believe that this solution can potentially play an important role
in the documented effectiveness of sanitation procedures and hygiene monitoring. It is planned that this
kit will also be used by hundreds of Eurofins testing laboratories around the world to offer fast
turnaround testing services to support their clients’ needs wherever necessary.” commented Dr. Gilles
Martin, Chief Executive Officer, Eurofins Scientific.
More information on this integrated testing solution can be found on https://www.eurofins-
technologies.com/products/viruses.html
For more information, please visit www.eurofins.com or contact:
Investor Relations
Eurofins Scientific
Phone: +32 2 766 1620
E-mail:
[email protected]
Notes for the editor:
About Eurofins – a global leader in bio-analysis
Eurofins Scientific, through its subsidiaries (hereinafter “Eurofins” or “the Group”), believes it is a global leader in food,
environmental, pharmaceutical and cosmetics products testing and in agroscience CRO services. It is also one of the global
independent market leaders in certain testing and laboratory services for genomics, discovery pharmacology, forensics,
CDMO, advanced material sciences and in the support of clinical studies. In addition, Eurofins is one of the leading global
emerging players in esoteric clinical diagnostic testing. With over 47,000 staff across a network of more than 900
Eurofins Scientific 1/2 March 2020
independent companies in over 50 countries generally specialised by end client markets and operating more than 800
laboratories, Eurofins offers a portfolio of over 200,000 analytical methods to evaluate the safety, identity, composition,
authenticity, origin, traceability and purity of biological substances and products, as well as providing innovative clinical
diagnostic testing services. The Group’s objective is to provide customers with high-quality and innovative services, accurate
results on time and, when requested, expert advice by its highly-qualified staff.
Eurofins is committed to pursuing its dynamic growth strategy by expanding both its technology portfolio and its geographic
reach. Through R&D and acquisitions, the Group draws on the latest developments in the field of biotechnology and
analytical chemistry to offer its clients unique analytical solutions and a very large range of testing methods.
As one of the most innovative and quality-oriented international companies in its industry, Eurofins is ideally positioned to
support its clients’ increasingly stringent quality and safety standards and the increasing demands of regulatory authorities
and healthcare practitioners around the world.
Shares in Eurofins Scientific are listed on the Euronext Paris Stock Exchange (ISIN FR0000038259, Reuters EUFI.PA,
Bloomberg ERF FP).
Until it has been lawfully made public widely by Eurofins through approved distribution channels, this document contains
inside information for the purpose of Regulation (EU) 596/2014 of the European Parliament and of the Council of 16 April
2014 on market abuse, as amended.
Important disclaimer:
This press release contains forward-looking statements and estimates that involve risks and uncertainties. The forward-
looking statements and estimates contained herein represent the judgment of Eurofins Scientific’s management as of the
date of this release. These forward-looking statements are not guarantees for future performance, and the forward-looking
events discussed in this release may not occur. Eurofins Scientific disclaims any intent or obligation to update any of these
forward-looking statements and estimates. All statements and estimates are made based on the information available to the
Company’s management as of the date of publication, but no guarantees can be made as to their completeness or validity.
Eurofins Scientific 2/2 March 2020
From:
[email protected] <
[email protected]>
Sent: Tuesday, April 14, 2020 2:19 PM
To: Riigikantselei <
[email protected]>
Subject: Eurofinsi laborite analüüsivõimekused seoses COVID-19 olukorraga
Tere Lgp. Peaminister,
kirjutan Teile keskkonnaanalüüse teostavast laborist Eurofins Estonia.
Peale keskkonnaanalüüside tegeleb meie globaalsest laboritevõrgustikust ettevõte (üle 800 labori) ka
paljude teiste erinevate analüüsidega, mida on võimalik otse meie kaudu tellida, sealhulgas toidu-,
keskkonna-, farmaatsia- ja kosmeetikatoodete testimine ning agroteaduste CRO-teenused. Lisaks
tegeleme ka genoomika, avastusfarmakoloogia, kohtuekspertiisi, CDMO, kõrgtehnoloogiliste
materjaliteaduste ning kliiniliste uuringutega.
Seoses koroonaviiruse olukorraga, sooviksime Eesti riigile pakkuda analüüside tellimuse võimalusi
Eurofinsi laboritelt, mille võimekus on hetkel globaalselt 15 000 katset/päevas.
Hetkel saaksime pakkuda 3 erinevat teenust:
1) SARS-CoV-2 inimestelt võetud proovidest
2) SARS-CoV-2 pindadelt võetud proovidest
3) Isikukaitsevahendite ja meditsiiniseadmete katsetamist, inspektsiooni ja sertifitseerimist.
Täpsema info jaoks palun võtke minuga ühendust ja lugege lähemalt infolehtedelt manuses ning lisaks
meie kodulehelt:
https://www.eurofins.com/about-us/covid-19/
https://www.eurofins.com/COVID-19-Global-Services
https://www.eurofins.com/media-centre/press-releases/
Küsimuste korral vastan Teile meeleldi!
Lugupidamisega,
Sander Sannik
Business Unit Manager
Mob +372 53002316
Labor +372 58837202
[email protected]